作　　者： (刘志军）; (袁兴东）; (张薇）; (徐玉茗）;

机构地区： 江西省药品不良反应监测中心,江西南昌330006

出　　处： 《中国药物警戒》 2017年第8期486-488,497,共4页

摘　　要： 目的分析鲑降钙素制剂不良反应(ADR)的发生特点,为临床合理用药提供科学依据。方法回顾性分析2010年~2016年江西省药品不良反应监测中心收集到的365例鲑降钙素制剂导致的ADR报告,总结患者的人口学分布特征、原发疾病与过敏史、给药方法,ADR发生的时间分布、因果关系及转归、累计系统-器官等。结果发生ADR的患者中女性占比达81.64%,60岁以上患者比例为69.59%;日使用剂量占比最高的为50 IU,占比54.80%;ADR发生在用药后10 min内的占比达34.79%;ADR累及系统-器官多达十余个,其中以胃肠道系统损伤最多。结论临床应加强对鲑降钙素制剂的用药后监测,同时生产企业应对药品说明书进一步补充和完善,以减少鲑降钙素制剂ADR的发生。 Objective To analyze the characteristics of adverse drug reaction （ADR） of salcatonin preparations and provide scientific basis for rational drug use. Methods 365 cases of ADR reports of salcatonin preparations, from 2010 to 2016, were analyzed retrospectively. Demographic characteristics, primary diseases and allergies, method of treatment, distribution time of ADR, causality and outcome, systems or organs involved were summarized. Results ADR occurred in female accounted for 81.64%, and age over 60 years accounted for 69.59%; The highest ratio of daily use dose were 50 IU, accounted for 54.80% ; ADR occurred within 10 min after medication accounted for 34.79%. Systems or organs involved were up to 10, and the gastrointestinal system were damaged most. Conclusions To reduce the occurrence of ADR of salcatonin preparations, medication monitoring should be strengthened, while drug instructions ought to make supplement and complete by production enterprises.

关 键 词： 鲑降钙素制剂 药品不良反应 回顾性分析